COMPANY

NeOnc Technologies

HQ: Calabasas, CA source · neonc.com ↗ · West Coast

Keywords: neurology IDH-Mutant Diffuse Astrocytoma IDH-wildtype Glioblastoma Adult Brain Metastases Cervical Cancer Colorectal Cancer Esophageal Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Head and Neck Squamous Cell Carcinoma Melanoma Merkel Cell Carcinoma Microsatellite Instability-High Solid Malignant Tumor Mismatch Repair Deficient Solid Malignant Tumor Microsatellite Instability-High Colorectal Cancer Mismatch Repair Deficient Colorectal Cancer Non-small Cell Lung Cancer Renal Cell Carcinoma Small Cell Lung Cancer Squamous Cell Carcinoma Urothelial Carcinoma Residual, Progressive or Recurrent Grade II or III Meningioma Pediatric Tumor of CNS Pediatric Tumor of Brain H3 K27M-Mutant Diffuse Midline Glioma Pediatric Tumor of Brain Stem Pineocytoma Childhood Choroid Plexus Carcinoma Spinal Cord Tumor High Grade Glioma Glioblastoma Multiforme acute myeloid leukemia NEO100 NEO212 Perillyl alcohol

Location: Calabasas, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$66.0MRaised (2 yrs)4Trials (company is sponsor)7NIH grants

Funding and NIH signals

SEC Form D raise Raised $5M (Form D filed Jun 25, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001829126-26-006874 (Jun 25, 2026)
Evidence (2 events)
- Jun 25, 2026 · SEC Form D 0001829126-26-006874
  Name of Issuer: NEONC TECHNOLOGIES HOLDINGS, INC.; CIK: 1979414; Address: Calabasas, CA; Submission type: D; Filing date: 2026-06-25; Industry Group: Biotechnology; Date of First Sale: 2026-06-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
- Dec 18, 2025 · SEC Form D 0001979414-25-000006
  Name of Issuer: NEONC TECHNOLOGIES HOLDINGS, INC.; CIK: 1979414; Address: Calabasas, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 1000000; Federal exemptions: 06b
NIH award NIH awarded $1.03M (STTR Phase II 5R42CA246902-04, continuation, notice Sep 14, 2026); 3 NIH awards totaling $2.44M in the last 12 months. NIH RePORTER 5R42CA246902-04 (Sep 14, 2026)
Evidence (3 events)
- Sep 14, 2026 · NIH RePORTER 5R42CA246902-04
  Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 5R42CA246902-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1033906; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits
- Jul 16, 2026 · NIH RePORTER 6R41CA271879-02
  Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R41CA271879-02; Activity code: R41; Fiscal year: 2025; Award notice date: 2026-07-16; FY total cost (award amount): 399998; Administering IC: National Cancer Institute; Project title: Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia; Organization type: Domestic For-Profits
- Jul 15, 2026 · NIH RePORTER 6R42CA246902-03
  Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R42CA246902-03; Activity code: R42; Fiscal year: 2025; Award notice date: 2026-07-15; FY total cost (award amount): 1007612; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 8, 2026 Trial start Phase 1: A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors source ↗
Jan 30, 2026 Raise Private placement: $16M (total, as published), announced Jan 30, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Feb 9, 2026 SEC Form D ↗
Aug 11, 2025 Partnership Partnership / licensing: upfront not published; stated deal value $50M (kept separate from upfront), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗
Aug 7, 2025 Grant Government grant: $2.5M (total, as published), announced Aug 7, 2025. Source: company release on GlobeNewswire. source ↗
Jul 22, 2025 Partnership Partnership / licensing: upfront not published; stated deal value $50M (kept separate from upfront), announced Jul 22, 2025. Source: company release on GlobeNewswire. source ↗
Jul 10, 2025 Raise Private placement: $50M (total, as published), announced Jul 10, 2025. Source: company release on GlobeNewswire. source ↗
Nov 1, 2023 Trial start Phase 1/Phase 2: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis source ↗
Jul 1, 2022 Trial start Phase 2: NEO100 and High-Grade Meningioma source ↗
Aug 1, 2017 Trial start Phase 1/Phase 2: Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma source ↗

Upcoming milestones

Nov 30, 2026 (ESTIMATED) · Phase 1/Phase 2 · Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma · NCT02704858
Dec 30, 2026 (ESTIMATED) · Phase 2 · NEO100 and High-Grade Meningioma · NCT05023018
Feb 28, 2027 (ESTIMATED) · Phase 1/Phase 2 · Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · NCT06047379
2027-06 (ESTIMATED) · Phase 1 · A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors · NCT06357377

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $66.0M. Last 2 years.

Jan 30, 2026 Private placement: $16M (total, as published), announced Jan 30, 2026. Source: company release on GlobeNewswire. source ↗ · Form D filed Feb 9, 2026 SEC Form D ↗
Jul 10, 2025 Private placement: $50M (total, as published), announced Jul 10, 2025. Source: company release on GlobeNewswire. source ↗
Aug 11, 2025 Partnership / licensing: upfront not published; stated deal value $50M (kept separate from upfront), announced Aug 11, 2025. Source: company release on GlobeNewswire. source ↗
Jul 22, 2025 Partnership / licensing: upfront not published; stated deal value $50M (kept separate from upfront), announced Jul 22, 2025. Source: company release on GlobeNewswire. source ↗
Aug 7, 2025 Government grant: $2.5M (total, as published), announced Aug 7, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Phase 1/Phase 2	Recruiting	Nov 1, 2023	Feb 28, 2027 (estimated)
NCT05023018	NEO100 and High-Grade Meningioma	Phase 2	Recruiting	Jul 1, 2022	Dec 30, 2026 (estimated)
NCT06357377	A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors	Phase 1	Recruiting	Sep 8, 2026	2027-06 (estimated)
NCT02704858	Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	Phase 1/Phase 2	Active, not recruiting	Aug 1, 2017	Nov 30, 2026 (estimated)

NIH awards 7

Annual award amounts. Total $3.4M.

Sep 14, 2026 NIH award 5R42CA246902-04 FY2026: $1,033,906 awarded for that fiscal year; activity R42 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES HOLDINGS INC., CALABASAS, CA. Developing a Clinically Relev source ↗
Jul 16, 2026 NIH award 6R41CA271879-02 FY2025: $399,998 awarded for that fiscal year; activity R41 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES HOLDINGS INC., CALABASAS, CA. Development of NEO212, A Novel source ↗
Jul 15, 2026 NIH award 6R42CA246902-03 FY2025: $1,007,612 awarded for that fiscal year; activity R42 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES HOLDINGS INC., CALABASAS, CA. Developing a Clinically Relev source ↗
Mar 25, 2020 NIH award 1R41CA246902-01A1 FY2020: $336,000 awarded for that fiscal year; activity R41 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES, INC., Calabasas, CA. Developing a clinically relevant radi source ↗
Aug 6, 2019 NIH award 3R41CA217551-01A1S1 FY2019: $1,450 awarded for that fiscal year; activity R41 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES, INC., Calabasas, CA. Innovative Nose-to-Brain Anticancer D source ↗
Mar 23, 2018 NIH award 1R41CA217551-01A1 FY2018: $300,000 awarded for that fiscal year; activity R41 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES, INC., Calabasas, CA. Innovative Nose-to-Brain Anticancer D source ↗
Jun 20, 2016 NIH award 1R41CA192419-01A1 FY2016: $300,000 awarded for that fiscal year; activity R41 (STTR); PI CHEN, THOMAS C.; recipient as written: NEONC TECHNOLOGIES, INC., Calabasas, CA. Temozolomide Perillyl Alcohol Conjuga source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2026-06-25 Raise Private raise (SEC Form D): $5.0M sold; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗
2026-02-09 Raise Private raise (SEC Form D): $10.6M sold of $36.0M offered; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗
2025-12-18 Raise Private raise (SEC Form D): $1.0M sold; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗
2025-04-11 Raise Private raise (SEC Form D): $1.6M sold of $2.0M offered; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗
2025-03-24 Raise Private raise (SEC Form D): $10.0M sold; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗
2024-10-28 Raise Private raise (SEC Form D): $18.3M sold of $18.7M offered; issuer “NEONC TECHNOLOGIES HOLDINGS, INC.”. Verified from the SEC filing. SEC filing ↗